The invention provides a pharmaceutical product comprising a first active ingredient which is N-[2-(Diethylamino)ethyl]-N-(2-[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor)=Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist which is Aclidinium bromide, Glycopyrrolate, Oxitropium bromide, Pirenzepine, telenzepine, Tiotropium bromide, 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azo-niabicyclo[2.2.2]octane bromide, 3(R)-
1
-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide or (3R)-3-[(2S)-2-cyclopentyl-2-hydroxy-2-thien-2-ylacetoxy]-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]actane bromide; a p38 inhibitor; a PDE inhibitor; a PPARy agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.
该发明提供了一种药物产品,包括第一活性成分为N-[2-(二乙
氨基)乙基]-N-(2-[2-(
4-羟基-2-氧代-2,3-二氢-1,3-
苯并噻唑-7-基)乙基]
氨基}乙基)-3-[2-(1-
萘基)乙氧基]丙酰胺或其盐,和第二活性成分从以下中选择:非甾体型糖皮质激素受体(GR受体)=激动剂;
抗氧化剂;CCR1拮抗剂;
趋化因子拮抗剂(非CCR1);类
固醇;CRTh2拮抗剂;DP1拮抗剂;组蛋白
去乙酰化酶诱导剂;IKK2
抑制剂;COX
抑制剂;脂氧合酶
抑制剂;
白三烯受体拮抗剂;MPO
抑制剂;Aclidinium
溴化物,Glycopyrrolate,Oxitropium
溴化物,Pirenzepine,telenzepine,Tiotropium
溴化物,3(R)-(2-羟基-2,2-二
噻吩-2-乙氧基)-1-(3-苯氧基丙基)-1-氮杂
双环[2.2.2]辛烷溴化物,3(R)-1-苯乙基-3-(9H-
黄酮-9-羰基氧基)-1-氮杂
双环[2.2.2]辛烷溴化物或(3R)-3-[(2S)-2-环戊基-2-羟基-2-
噻吩-2-乙氧基]-1-(2-苯氧基乙基)-1-氮杂
双环[2.2.2]辛烷溴化物;p38
抑制剂;PDE
抑制剂;
PPARy激动剂;蛋白酶抑制剂;他汀类药物;血栓素受体拮抗剂;血管扩张剂;或E
NAC阻滞剂(上皮
钠通道阻滞剂),以及其在呼吸道疾病治疗中的应用。